QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VCYT

QT79Veracyte, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
53.63
+2.34+4.56%
OverviewShort InterestFilings
VCYTQT79Veracyte, Inc.·NASDAQ
OverviewShort InterestFilings
53.63+4.56%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E46.35EPS (ttm)
1.08
Insider Own2.88%
Shs Outstand79.79M
Perf Week13.10%
Market Cap4.09BForward P/E28.26EPS next Y1.90Insider Trans0.04%Shs Float-Perf Month28.64%
Enterprise Value3.87BPEG0.29EPS next Q0.44Inst Own-Short Float-Perf Quarter63.61%
Income88.40MP/S7.55EPS this Y69.32%Inst Trans-Short Ratio-Perf Half Y24.09%
Sales541.74MP/B3.03EPS next Y3.79%ROA6.13%Short Interest-Perf YTD27.39%
Book/sh16.84P/C24.55EPS next 5Y4.81%ROE6.86%52W High53.81 -0.33%Perf Year100.41%
Cash/sh5.50P/FCF26.44EPS past 3/5Y-ROIC4.73%52W Low22.61 137.20%Perf 3Y-
Dividend Est.-EV/EBITDA34.47Sales past 3/5Y20.29% 34.60%Gross Margin71.31%Volatility3.25% 3.28%Perf 5Y-
Dividend TTM-EV/Sales7.14EPS Y/Y TTM545.16%Oper. Margin12.45%ATR (14)2.38Perf 10Y-
Dividend Ex-Date-Quick Ratio8.92Sales Y/Y TTM21.52%Profit Margin16.25%RSI (14)72.92Recom2.67
Dividend Gr. 3/5Y-Current Ratio9.31EPS Q/Q67.74%SMA2011.61%Beta1.66Target Price47.60
Payout0.00%Debt/Eq0.03Sales Q/Q21.93%SMA5031.68%Rel Volume3.63Prev Close51.29
Employees824LT Debt/Eq0.03EarningsAug 05SMA20039.54%Avg Volume1.14MPrice53.63
IPO DateOct 30, 2013Option/ShortYes / YesEPS/Sales Surpr.52.94% 6.92%Net Debt/EBITDA-1.99Volume4,125,792Change4.56%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26ReiteratedNeedhamBuy$44 → $57
May-28-26ReiteratedNeedhamBuy$44 → $57
May-06-26ReiteratedUBSBuy$48 → $52
May-06-26ReiteratedCanaccord GenuityHold$43 → $42
Jan-05-26ReiteratedGuggenheimBuy$50
Nov-05-25ReiteratedCanaccord GenuityHold$40 → $43
Nov-05-25ReiteratedUBSBuy$48
Oct-20-25InitiatedCanaccordHold$40
Aug-08-25ReiteratedMorgan StanleyUnderweight$29 → $28
Dec-05-24DowngradeGoldman SachsBuy → Neutral
Latest News
Jun-16-26
Jun-16-2612:00PM
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)ChartMill
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue542517446
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A155157148
Gross Profit387360298
Selling, General and Administrative Excl. Other203211206
Research and Development807169
Other Operating Expense3647
Operating Income687416
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-246-10
Net Income Before Taxes916826
Income Taxes222
Consolidated Net Income886624
Net Income From Continuing Operations886624
Net Income886624
EPS (Recurring)1.110.840.32
EPS (Basic, Before Extraordinaries)1.110.840.32
EPS (Diluted)1.080.820.31
EBITDA1129049
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio49.6651.34—
Price To Sales Ratio7.926.43—
Gross Margin71.4069.6366.82
Operating Margin12.5514.313.59
Net Margin16.2412.775.38
Shares Outstanding807976
Market Capitalization4,2903,326—
Operating Lease Expense
———
Insider Trading Volume
$56.41$50.95$45.49$40.03$34.57● Close Price0.00M1.99M3.98M5.97M7.95MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Stapley MarcChief Executive OfficerJun 04 '26Option Exercise36.60276,10210,105,334578,545Jun 04 12:00 AM
Stapley MarcChief Executive OfficerJun 04 '26Sale50.12138,0516,919,585440,494Jun 04 12:00 AM
Leite JohnGlobal Chief Commercial OffJun 04 '26Sale50.0713,975699,732132,305Jun 04 12:00 AM
McGuire AnnieEVP, General CounselJun 04 '26Sale49.763,176158,036137,240Jun 04 12:00 AM
Chambers RebeccaChief Financial OfficerJun 04 '26Sale49.733,561177,083173,280Jun 04 12:00 AM
Wygant JonathanVP, Chief Accounting OfficerMay 22 '26Option Exercise24.8048,0001,190,40069,434May 27 12:00 AM
Wygant JonathanVP, Chief Accounting OfficerMay 22 '26Sale45.4024,0001,089,62445,434May 27 12:00 AM
EPSTEIN ROBERT SDirectorMay 20 '26Sale44.0110,000440,12952,446May 22 12:00 AM
McGuire AnnieSVP, General CounselMay 06 '26Sale39.0210,204398,211143,708May 08 12:00 AM
Stapley MarcChief Executive OfficerMar 04 '26Sale35.9745,5231,637,594357,554Mar 06 12:00 AM
Leite JohnChief Commercial Officer-CLIAMar 04 '26Sale35.195,260185,083107,580Mar 06 12:00 AM
McGuire AnnieSVP, General CounselMar 04 '26Sale35.556,658236,72594,706Mar 06 12:00 AM
Chambers RebeccaChief Financial OfficerMar 04 '26Sale36.1418,341662,869131,196Mar 06 12:00 AM
Febbo Phillip G.Chief Scientific & Med OfficerMar 02 '26Sale36.1613,425485,429117,346Mar 04 12:00 AM
McGuire AnnieSVP, General CounselDec 16 '25Sale43.1310,739463,20467,760Dec 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR